173 related articles for article (PubMed ID: 12753299)
1. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats.
Alderson NL; Chachich ME; Youssef NN; Beattie RJ; Nachtigal M; Thorpe SR; Baynes JW
Kidney Int; 2003 Jun; 63(6):2123-33. PubMed ID: 12753299
[TBL] [Abstract][Full Text] [Related]
2. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.
Degenhardt TP; Alderson NL; Arrington DD; Beattie RJ; Basgen JM; Steffes MW; Thorpe SR; Baynes JW
Kidney Int; 2002 Mar; 61(3):939-50. PubMed ID: 11849448
[TBL] [Abstract][Full Text] [Related]
3. Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat.
Muellenbach EA; Diehl CJ; Teachey MK; Lindborg KA; Archuleta TL; Harrell NB; Andersen G; Somoza V; Hasselwander O; Matuschek M; Henriksen EJ
Metabolism; 2008 Oct; 57(10):1465-72. PubMed ID: 18803954
[TBL] [Abstract][Full Text] [Related]
4. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications.
Metz TO; Alderson NL; Chachich ME; Thorpe SR; Baynes JW
J Biol Chem; 2003 Oct; 278(43):42012-9. PubMed ID: 12923193
[TBL] [Abstract][Full Text] [Related]
5. Pyridoxamine prevents age-related aortic stiffening and vascular resistance in association with reduced collagen glycation.
Wu ET; Liang JT; Wu MS; Chang KC
Exp Gerontol; 2011 Jun; 46(6):482-8. PubMed ID: 21316441
[TBL] [Abstract][Full Text] [Related]
6. Pyridoxamine inhibits maillard reactions in diabetic rat lenses.
Padival S; Nagaraj RH
Ophthalmic Res; 2006; 38(5):294-302. PubMed ID: 16974131
[TBL] [Abstract][Full Text] [Related]
7. Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats.
Waanders F; van den Berg E; Nagai R; van Veen I; Navis G; van Goor H
Nephrol Dial Transplant; 2008 Feb; 23(2):518-24. PubMed ID: 17905804
[TBL] [Abstract][Full Text] [Related]
8. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications.
Metz TO; Alderson NL; Thorpe SR; Baynes JW
Arch Biochem Biophys; 2003 Nov; 419(1):41-9. PubMed ID: 14568007
[TBL] [Abstract][Full Text] [Related]
9. Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat.
Alderson NL; Chachich ME; Frizzell N; Canning P; Metz TO; Januszewski AS; Youssef NN; Stitt AW; Baynes JW; Thorpe SR
Diabetologia; 2004 Aug; 47(8):1385-95. PubMed ID: 15309289
[TBL] [Abstract][Full Text] [Related]
10. Renoprotective and lipid-lowering effects of LR compounds, novel advanced glycation end product inhibitors, in streptozotocin-induced diabetic rats.
Figarola JL; Scott S; Loera S; Xi B; Synold T; Rahbar S
Ann N Y Acad Sci; 2005 Jun; 1043():767-76. PubMed ID: 16037304
[TBL] [Abstract][Full Text] [Related]
11. Adverse renal effects of the AGE inhibitor pyridoxamine in combination with ACEi in non-diabetic adriamycin-induced renal damage in rats.
Waanders F; van Goor H; Navis G
Kidney Blood Press Res; 2008; 31(5):350-9. PubMed ID: 19018148
[TBL] [Abstract][Full Text] [Related]
12. The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in Zucker obese rats.
Aldini G; Orioli M; Rossoni G; Savi F; Braidotti P; Vistoli G; Yeum KJ; Negrisoli G; Carini M
J Cell Mol Med; 2011 Jun; 15(6):1339-54. PubMed ID: 20518851
[TBL] [Abstract][Full Text] [Related]
13. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal.
Nagaraj RH; Sarkar P; Mally A; Biemel KM; Lederer MO; Padayatti PS
Arch Biochem Biophys; 2002 Jun; 402(1):110-9. PubMed ID: 12051689
[TBL] [Abstract][Full Text] [Related]
14. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine.
Onorato JM; Jenkins AJ; Thorpe SR; Baynes JW
J Biol Chem; 2000 Jul; 275(28):21177-84. PubMed ID: 10801874
[TBL] [Abstract][Full Text] [Related]
15. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes.
Stitt A; Gardiner TA; Alderson NL; Canning P; Frizzell N; Duffy N; Boyle C; Januszewski AS; Chachich M; Baynes JW; Thorpe SR
Diabetes; 2002 Sep; 51(9):2826-32. PubMed ID: 12196477
[TBL] [Abstract][Full Text] [Related]
16. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice.
Tanimoto M; Gohda T; Kaneko S; Hagiwara S; Murakoshi M; Aoki T; Yamada K; Ito T; Matsumoto M; Horikoshi S; Tomino Y
Metabolism; 2007 Feb; 56(2):160-7. PubMed ID: 17224327
[TBL] [Abstract][Full Text] [Related]
17. Prevention of early renal disease, dyslipidaemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors.
Figarola JL; Scott S; Loera S; Xi B; Synold T; Weiss L; Rahbar S
Diabetes Metab Res Rev; 2005; 21(6):533-44. PubMed ID: 15818713
[TBL] [Abstract][Full Text] [Related]
18. Reaction of pyridoxamine with malondialdehyde: mechanism of inhibition of formation of advanced lipoxidation end-products.
Kang Z; Li H; Li G; Yin D
Amino Acids; 2006 Feb; 30(1):55-61. PubMed ID: 15990947
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.
Miyata T; Horie K; Ueda Y; Fujita Y; Izuhara Y; Hirano H; Uchida K; Saito A; van Ypersele de Strihou C; Kurokawa K
Kidney Int; 2000 Jul; 58(1):425-35. PubMed ID: 10886591
[TBL] [Abstract][Full Text] [Related]
20. Novel inhibitors of glycation and AGE formation.
Rahbar S
Cell Biochem Biophys; 2007; 48(2-3):147-57. PubMed ID: 17709884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
